S&P 500   3,781.56 (-0.37%)
DOW   30,923.23 (-0.22%)
QQQ   313.15 (-0.38%)
AAPL   128.06 (-0.66%)
MSFT   213.76 (+0.35%)
FB   251.77 (+2.50%)
GOOGL   1,741.72 (+0.62%)
AMZN   3,110.18 (-0.55%)
TSLA   831.19 (-1.63%)
NVDA   519.90 (-1.54%)
BABA   243.87 (+0.37%)
CGC   33.83 (-2.28%)
GE   11.42 (-2.06%)
MU   81.10 (-0.25%)
AMD   88.96 (-2.02%)
T   29.15 (-0.48%)
NIO   56.93 (-6.47%)
F   9.93 (-2.36%)
ACB   12.16 (+1.67%)
BA   205.79 (-1.96%)
DIS   171.36 (-1.19%)
NFLX   500.21 (-0.13%)
GILD   63.39 (+1.59%)
S&P 500   3,781.56 (-0.37%)
DOW   30,923.23 (-0.22%)
QQQ   313.15 (-0.38%)
AAPL   128.06 (-0.66%)
MSFT   213.76 (+0.35%)
FB   251.77 (+2.50%)
GOOGL   1,741.72 (+0.62%)
AMZN   3,110.18 (-0.55%)
TSLA   831.19 (-1.63%)
NVDA   519.90 (-1.54%)
BABA   243.87 (+0.37%)
CGC   33.83 (-2.28%)
GE   11.42 (-2.06%)
MU   81.10 (-0.25%)
AMD   88.96 (-2.02%)
T   29.15 (-0.48%)
NIO   56.93 (-6.47%)
F   9.93 (-2.36%)
ACB   12.16 (+1.67%)
BA   205.79 (-1.96%)
DIS   171.36 (-1.19%)
NFLX   500.21 (-0.13%)
GILD   63.39 (+1.59%)
S&P 500   3,781.56 (-0.37%)
DOW   30,923.23 (-0.22%)
QQQ   313.15 (-0.38%)
AAPL   128.06 (-0.66%)
MSFT   213.76 (+0.35%)
FB   251.77 (+2.50%)
GOOGL   1,741.72 (+0.62%)
AMZN   3,110.18 (-0.55%)
TSLA   831.19 (-1.63%)
NVDA   519.90 (-1.54%)
BABA   243.87 (+0.37%)
CGC   33.83 (-2.28%)
GE   11.42 (-2.06%)
MU   81.10 (-0.25%)
AMD   88.96 (-2.02%)
T   29.15 (-0.48%)
NIO   56.93 (-6.47%)
F   9.93 (-2.36%)
ACB   12.16 (+1.67%)
BA   205.79 (-1.96%)
DIS   171.36 (-1.19%)
NFLX   500.21 (-0.13%)
GILD   63.39 (+1.59%)
S&P 500   3,781.56 (-0.37%)
DOW   30,923.23 (-0.22%)
QQQ   313.15 (-0.38%)
AAPL   128.06 (-0.66%)
MSFT   213.76 (+0.35%)
FB   251.77 (+2.50%)
GOOGL   1,741.72 (+0.62%)
AMZN   3,110.18 (-0.55%)
TSLA   831.19 (-1.63%)
NVDA   519.90 (-1.54%)
BABA   243.87 (+0.37%)
CGC   33.83 (-2.28%)
GE   11.42 (-2.06%)
MU   81.10 (-0.25%)
AMD   88.96 (-2.02%)
T   29.15 (-0.48%)
NIO   56.93 (-6.47%)
F   9.93 (-2.36%)
ACB   12.16 (+1.67%)
BA   205.79 (-1.96%)
DIS   171.36 (-1.19%)
NFLX   500.21 (-0.13%)
GILD   63.39 (+1.59%)
Log in
NASDAQ:AMRS

Amyris Stock Forecast, Price & News

$11.43
+0.98 (+9.38 %)
(As of 01/15/2021 02:33 PM ET)
Add
Compare
Today's Range
$10.11
Now: $11.43▼
$11.76
50-Day Range
$2.63
MA: $5.15▼
$9.35
52-Week Range
$1.40
Now: $11.43▼
$10.84
Volume496,680 shs
Average Volume7.13 million shs
Market Capitalization$2.73 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.04
Amyris, Inc., a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company's technology platform enables to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. It applies technology platform to engineer, manufacture, and sell products for the clean health and beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Amyris logo

MarketRank™

Overall MarketRank™

1.14 out of 5 stars

Basic Materials Sector

230th out of 631 stocks

Industrial Organic Chemicals Industry

13th out of 29 stocks

Analyst Opinion: 1.5Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
Current SymbolNASDAQ:AMRS
Previous Symbol
CUSIP03236M10
CIK1365916
Webamyris.com
Phone510-450-0761
Employees561

Debt

Debt-to-Equity RatioN/A
Current Ratio1.27
Quick Ratio0.91

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$152.56 million
Price / Sales17.92
Cash FlowN/A
Price / Cash FlowN/A
Book Value($2.17) per share
Price / Book-5.27

Profitability

EPS (Most Recent Fiscal Year)($2.72)
Net Income$-242,770,000.00
Net Margins-223.41%
Return on EquityN/A
Return on Assets-149.25%

Miscellaneous

Outstanding Shares239,211,000
Market Cap$2.73 billion
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable
$11.43
+0.98 (+9.38 %)
(As of 01/15/2021 02:33 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amyris (NASDAQ:AMRS) Frequently Asked Questions

How has Amyris' stock been impacted by Coronavirus (COVID-19)?

Amyris' stock was trading at $2.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AMRS stock has increased by 284.1% and is now trading at $11.37.
View which stocks have been most impacted by COVID-19.

Is Amyris a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amyris stock.
View analyst ratings for Amyris or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Amyris?

Wall Street analysts have given Amyris a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amyris wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Amyris' next earnings date?

Amyris is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Amyris.

How were Amyris' earnings last quarter?

Amyris, Inc. (NASDAQ:AMRS) announced its quarterly earnings results on Tuesday, November, 10th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.20. The biotechnology company earned $34.26 million during the quarter, compared to analysts' expectations of $38.76 million.
View Amyris' earnings history.

When did Amyris' stock split? How did Amyris' stock split work?

Amyris shares reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for AMRS?

4 analysts have issued 12-month price objectives for Amyris' shares. Their forecasts range from $3.35 to $9.00. On average, they expect Amyris' share price to reach $7.12 in the next twelve months. This suggests that the stock has a possible downside of 37.4%.
View analysts' price targets for Amyris or view Wall Street analyst' top-rated stocks.

Who are some of Amyris' key competitors?

Some companies that are related to Amyris include Phillips 66 (PSX), Marathon Petroleum (MPC), Valero Energy (VLO), HollyFrontier (HFC), Renewable Energy Group (REGI), World Fuel Services (INT), Clean Energy Fuels (CLNE), CVR Energy (CVI), Delek US (DK), PBF Energy (PBF), Gevo (GEVO), Green Plains (GPRE), REX American Resources (REX) and Adams Resources & Energy (AE).
View all of AMRS's competitors.

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

Who are Amyris' key executives?

Amyris' management team includes the following people:
  • Mr. John G. Melo, Pres, CEO & Director (Age 55, Pay $1.15M)
  • Mr. Eduardo Alvarez, Chief Operating Officer (Age 57, Pay $665.19k)
  • Ms. Kathleen Valiasek, Chief Bus. Officer (Age 57, Pay $588.08k)
  • Mr. Hermanus Kieftenbeld, Chief Financial Officer (Age 55)
  • Mr. Anthony Hughes, Chief Accounting Officer (Age 56)
  • Mr. Peter DeNardo, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 55)
  • Ms. Beth Baker Bannerman, Sr. VP of Corp. Communications & Engagement
  • Ms. Christine Ofori, Chief People Officer
  • Mr. Charles Kraft, Sr. VP of Global Manufacturing & Process Devel.

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $11.37.

How big of a company is Amyris?

Amyris has a market capitalization of $2.72 billion and generates $152.56 million in revenue each year. The biotechnology company earns $-242,770,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Amyris employs 561 workers across the globe.

What is Amyris' official website?

The official website for Amyris is amyris.com.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]myris.com.

This page was last updated on 1/15/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.